-
Hunan Warrant Pharmaceutical’s ZG-002 Receives NMPA Approval for Clinical Trials in Plaque Psoriasis
•
Hunan Warrant Pharmaceutical Co., Ltd, a pharmaceutical company based in China and listed on the Shanghai Stock Exchange’s Science and Technology Innovation Board (SHA: 688799), has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug candidate, ZG-002. This new molecule is intended for…
-
Hunan Warrant Pharmaceutical’s ZG-001 Approved for Clinical Trial by NMPA
•
Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, ZG-001, intended to treat adults with major depressive disorder with acute suicidal ideation or behavior (MDSI). ZG-001’s Mechanism and Pre-Clinical Efficacy…
